Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q4 2016 · 10-K
Revenue$5.42M$5.42Mno prior Q4 2015 on file Net Income-$88.45M-$88.45MN/M vs Q4 2015 EPS Diluted-$1.62-$1.62N/M vs Q4 2015 Operating Income-$88,395,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$84,147,000N/M Margins · derivedOperating margin-1630.6%
Net margin-1631.7%
ended Dec 31, 2016 · filed Feb 28, 2017 · 59 d after period end